Nektar Therapeutics
Nektar Therapeutics (NKTR) Stock Ownership
Institutional vs insider vs public ownership from 13F and float data — top holders, activity, and insider trades below.
SEC 13F · FMP · NKTR · as of Sep 30, 2025
Ownership Breakdown
161
Institutional Holders
▲ 49 vs Q2
$820.11M
Total Inst. Value
▲ $622.26M vs Q2
19.54M
Shares Outstanding
freeFloat 93.79%
14.41M
13F Shares Held
▲ 6.75M vs Q2
Institutional ownership = 13F shares ÷ total outstanding. Insider % = 100 − free float. Public % = free float − institution %. Data: FMP /symbol-positions-summary + /shares-float + SEC EDGAR.
Top Institutional Holders
NKTR largest shareholders · institutional ownership
Q3 2025 · SEC 13F
Showing top 10 holders
| Holder | Shares | % Owned | Weight | Value | Reported | Change |
|---|---|---|---|---|---|---|
BVF INC/IL pharmaceutical preparations | 1.28M | 9.06% | 9.06% | $72.64B | Nov 14, 2025 | NEW |
VANGUARD GROUP INC pharmaceutical preparations | 948.6K | 6.73% | 6.73% | $53.98B | Nov 7, 2025 | ▲ 219.2K |
MORGAN STANLEY pharmaceutical preparations | 929.2K | 6.60% | 6.60% | $52.87B | May 27, 2026 | ▲ 857.0K |
SUSQUEHANNA INTERNATIONAL GROUP, LLP pharmaceutical preparations | 924.9K | 6.57% | 6.57% | $52.63B | Nov 14, 2025 | ▲ 703.0K |
FARALLON CAPITAL MANAGEMENT LLC pharmaceutical preparations | 791.0K | 5.62% | 5.62% | $45.01B | Feb 17, 2026 | NEW |
BLACKROCK, INC. pharmaceutical preparations | 609.1K | 4.32% | 4.32% | $34.66B | Nov 12, 2025 | ▲ 193.9K |
SUSQUEHANNA INTERNATIONAL GROUP, LLP pharmaceutical preparations | 548.2K | 3.89% | 3.89% | $31.19B | Nov 14, 2025 | ▼ 92.1K |
MILLENNIUM MANAGEMENT LLC pharmaceutical preparations | 546.0K | 3.88% | 3.88% | $31.07B | Nov 14, 2025 | ▼ 103.0K |
TWO SIGMA INVESTMENTS, LP pharmaceutical preparations | 434.2K | 3.08% | 3.08% | $24.71B | Nov 14, 2025 | ▲ 354.8K |
NANTAHALA CAPITAL MANAGEMENT, LLC pharmaceutical preparations | 418.5K | 2.97% | 2.97% | $23.81B | Nov 14, 2025 | ▼ 291.2K |
Data from SEC Form 13F filings. Ownership bar normalised to largest holder. Change flags: isNew / isSoldOut / changeInSharesNumber (FMP extract-analytics/holder).
Institutional Activity
Q3 2025 vs prior quarter
Q3 2025
22
Increased
+3.63M shares18
New Positions
first time holders9
Decreased
−1.04M shares0
Sold Out
fully exitedNet shares change (top 50)
+2.59M
+3.63M / −1.04M
Net new holders
+31
18 new / 0 exited
Based on top 50 institutional holders by position size. Fields: isNew, isSoldOut, changeInSharesNumber (FMP extract-analytics/holder, limit=50).
Insider Buying vs Selling
NKTR insider trading · insider activity
Source: SEC Form 4
Insiders have been primarily selling shares recently. Selling may be driven by pre-scheduled Rule 10b5-1 plans rather than negative sentiment.
0
Buy transactions
2
Sell transactions
0.00
Buy/Sell ratio
$0M
Total disposed
Recent Insider Transactions
Showing 10 most recent · Common Stock only
| Name · Role | Date | Type | Shares | Price | Value | After Trans. | Filing |
|---|---|---|---|---|---|---|---|
Zalevsky Jonathan Chief R&D Officer | May 19, 2026 | Sale | 199 | $65.51 | $13.0K | 21.0K | Form 4 ↗ |
ROBIN HOWARD W President & CEO | May 19, 2026 | Sale | 444 | $65.51 | $29.1K | 75.0K | Form 4 ↗ |
Zalevsky Jonathan Chief R&D Officer | Feb 18, 2026 | Sale | 180 | $73.00 | $13.1K | 21.2K | Form 4 ↗ |
ROBIN HOWARD W President & CEO | Feb 18, 2026 | Sale | 423 | $73.00 | $30.9K | 75.5K | Form 4 ↗ |
Zalevsky Jonathan Chief R&D Officer | Jan 20, 2026 | Sale | 3,867 | $35.67 | $137.9K | 21.4K | Form 4 ↗ |
Zalevsky Jonathan Chief R&D Officer | Dec 22, 2025 | Award | 6,250 | — | — | 25.2K | Form 4 ↗ |
Zalevsky Jonathan Chief R&D Officer | Dec 22, 2025 | Award | 25,000 | $43.48 | $1.09M | 25.0K | Form 4 ↗ |
ROBIN HOWARD W President & CEO | Dec 22, 2025 | Award | 86,667 | $43.48 | $3.77M | 86.7K | Form 4 ↗ |
ROBIN HOWARD W President & CEO | Dec 22, 2025 | Award | 21,667 | — | — | 75.9K | Form 4 ↗ |
Zalevsky Jonathan Chief R&D Officer | Nov 21, 2025 | Award | 2,666 | — | — | 20.1K | Form 4 ↗ |
Source: /insider-trading/search (FMP stable). Buy/Sell direction: acquisitionOrDisposition A=Buy, D=Sell. RSU vesting (M-Exempt) excluded from sentiment bar. All data from SEC EDGAR public filings.
About institutional & insider ownership
Nektar Therapeutics (NKTR) is primarily owned by institutional investors, who hold approximately 73.7% of total shares outstanding. Company insiders own approximately 6.21%, while retail and public investors account for the remaining 20.06%.
The largest institutional shareholder of Nektar Therapeutics is BVF INC/IL, holding approximately 1.28 million shares — equal to 9.06% of outstanding shares — as of September 30, 2025.
A total of 161 institutional investors currently hold NKTR stock, with a combined institutional value of approximately $820,109,515 as of the most recent 13F filing period.
Frequently asked questions
NKTR ownershipNektar Therapeutics (NKTR) is primarily owned by institutional investors, who hold approximately 73.7% of shares. The largest shareholder is BVF INC/IL with a 9.06% stake. Company insiders hold 6.21%. Data sourced from SEC Form 13F as of September 30, 2025.